They found that diverse and often polyclonal putative BRCA1 or BRCA2 reversion mutations were identified in cfDNA from four OC patients (21%) and two breast cancer patients (Weigelt et al., 2017). The gene discussed is BRCA1; the disease is breast carcinoma.